Evidence map›Paper›PMID 40849720›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2025

METCAM/MUC18 is a Biomarker and Therapeutic Target for Prostate Cancer.

Guang-Jer Wu, Chia-Chi Hsieh, Yan-Cheng Fu, Yin-Huan Chuang, Yu-Chun Wei, Yuan-Hung Pong, Yenn-Rong Su, Vincent F-S Tsai, Jui-Chuang Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guang-Jer WuCancer Metastasis Laboratory, Department of Bioscience Technology, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.ORCID 0000-0003-1485-9169
Chia-Chi HsiehBiochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.
Yan-Cheng FuBiochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.
Yin-Huan ChuangBiochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.
Yu-Chun WeiBiochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.
Yuan-Hung PongDepartment of Urology, Ten Chen General Hospital, Yang-Mei District, Taoyuan city, 326, Taiwan.
Yenn-Rong SuDepartment of Urology, National Taiwan University Hospital Hsin-Chu branch, Hsin-Chu city, 300, Taiwan.
Vincent F-S TsaiDepartment of Urology, National Taiwan University, Taipei, Taiwan.
Jui-Chuang WuBiochemical Engineering Laboratory, Department of Chemical Engineering, Chung Yuan Christian University, Chung-li District, Taoyuan City, 32023, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMETCAM/MUC18 may be a new serum biomarker for predicting malignant propensity of prostate cancer by using a modified lateral flow immune assay (modified LFIA), which used the extremely high affinity between biotin and streptavidin and two antibody combinations to increase the sensitivity and specificity of traditional LFIA. To increase the sensitivity and specificity to the highest degree, in this report we further improved this modified LFIA by using a new antibody combination, which includes a biotinylated home-made chicken antibody and a nano-gold conjugated rabbit antibody (MBS416853). MATERIALS AND

methodsA calibration curve was established from two recombinant METCAM/MUC18 proteins (C-terminus GST as the positive control and NM-GST the negative control) and used for determining METCAM/MUC18 concentrations in 36 serum specimens from normal individuals and patients of benign prostatic hypertrophy (BPH) patients, prostatic intraepithelial neoplasia (PIN), and prostate cancer at various Gleason scores and after treatment.

resultsThe data obtained were much better than the previously modified LFIA, traditional LFIA, and PSA test. Serum METCAM/MUC18 concentrations were higher in pre-malignant PIN patients than prostate cancer patients and both were higher than normal individuals, BPH patients, and treated patients. Serum METCAM/MUC18 concentrations were directly proportional to most serum PSA concentrations.

conclusionsThe elevated serum METCAM/MUC18 concentration suggest that METCAM/MUC18 may be used as a novel biomarker for predicting the malignant potential of prostate cancer at the early premalignant (PIN) stage. Since METCAM/MUC18 could also drive the spreading of prostate cancer cells, METCAM/MUC18 may be a therapeutic target for the cancer.

Indexed as

Biomarkers, TumorCD146 AntigenProstatic HyperplasiaProstatic Intraepithelial NeoplasiaProstatic NeoplasmsAgedCase-Control StudiesFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorCD146 AntigenMCAM protein, humanbiotinylated antibodiesmodified LFIAnano-gold conjugated antibodiespremalignant stagestreptavidin

Identifiers

PMID40849720
PMCPMC12661251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.